The Pharmacist

JUNE 11, 2024

The Conservative Party has set out spending plans of £250m each year on Pharmacy First from 2027 to 2030, as it pledges to expand the service to include more conditions like acne and chest infections.

Documentation 74

Documentation 74

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Sartorius AG and Merck KGaA, Single-use technology propelling upstream bioprocessing market expansion The post Single-use bioreactor market to witness favourable expansion to 2030 appeared first on European Pharmaceutical Review.

Compounding 52

Compounding Vaccines 52

European Pharmaceutical Review

JUNE 28, 2023

million by 2030, growing at a compound annual growth rate (CAGR) of 5.57 percent from 2023 to 2030. percent between 2023 and 2030. percent from 2023 to 2030. The post HPLC market projected to value $8 million by 2030 appeared first on European Pharmaceutical Review. What is driving the HPLC market?

Drug Development 98

Drug Development Compounding 98

European Pharmaceutical Review

JULY 18, 2023

billion by 2030. Digitalisation to boost quality management systems market The post QMS market to value nearly $4b by 2030 appeared first on European Pharmaceutical Review. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Documentation 98

Documentation Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 98

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. The Asia Pacific region is expected to register the fastest growth from 2022-2030 due to the presence of the large HPAPI manufacturers in China. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105

Dosage Vaccines 105

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. billion by 2030 appeared first on European Pharmaceutical Review. According to a market report , the global RNA therapy clinical trials market is anticipated to reach $3.5

Vaccines 98

Vaccines 98

Express Pharma

JUNE 4, 2024

billion by 2030 Proteolysis targeting chimeras (PROTACs) are a promising approach to cancer treatment, yet after over two decades of research, not a single PROTAC has gained FDA approval. billion by 2030, according to GlobalData, a leading data and analytics company. billion in sales by 2030.

Compounding 92

Compounding Immunity Immunization 92

Express Pharma

APRIL 18, 2023

billion in 2030 at a compound annual growth rate (CARG) of 4.6 GlobalData’s latest report, ‘Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update’ , identified the potential launch of 10 new pipeline products as the main driver of the market’s growth. billion in 2030. billion in 2020 to $29.8

Compounding 98

Compounding 98

Express Pharma

MARCH 17, 2023

India is set to become a major player in the global nutraceutical industry, with a projected $100 billion valued market by 2030. For more information, see the report: [link] The post An AI tool to catalyse Mission $100 billion nutraceutical India by 2030 appeared first on Express Pharma.

105

105

STAT

OCTOBER 21, 2024

Scientific experts tasked with advising federal officials drafting the 2025-2030 Dietary Guidelines for Americans said the data were far too limited to draw conclusions. If you were hoping to see where ultra-processed foods might fit in the next Dietary Guidelines for Americans, hold that thought.

362

362

STAT

MAY 19, 2023

Viral hepatitis affects almost 400 million people and kills more than 1 million each year. Yet it was left off the agenda of the Millennium Development Goals.

Vaccines 254

Vaccines 254

STAT

OCTOBER 22, 2024

The experts charged with advising federal health officials on the 2025-2030 Dietary Guidelines for Americans had to scale a mountain of research challenges like this basic impediment, starting with the impossibility of randomly assigning people to eat only x or y for 30 to 40 years. People eat foods, not nutrients.

335

335

The Guardian - Pharmaceutical Industry

MAY 21, 2024

As the company prepared to present its growth plans to shareholders at its labs and corporate headquarters in Cambridge, it said many of the 20 new drugs will have the potential to generate more than $5bn in annual revenues at their peak.

55

55

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Generic Medicine 96

Generic Medicine Chemotherapy 96

pharmaphorum

OCTOBER 26, 2020

CRA’s Life Sciences Practice recently conducted an analysis of the barriers that currently limit reimbursement for many preventive care services and how the evolution of healthcare systems and preventive care offerings could change the demand and uptake of preventive care by 2030. How could payer views change by 2030?

Vaccines 130

Vaccines 130

European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. by 2030 appeared first on European Pharmaceutical Review. The global buccal drug delivery market is projected to grow from $3.38

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

AUGUST 17, 2022

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. According to a recent report , the global formulation development outsourcing market size should grow to $61.4

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 96

European Pharmaceutical Review

OCTOBER 7, 2022

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 billion by 2030 appeared first on European Pharmaceutical Review. A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 98

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 98

PharmaVoice

MAY 23, 2024

Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.

130

130

PharmaVoice

FEBRUARY 20, 2024

By 2030, the AI market is expected to reach $187.95 A significant growth is predicted for both AI and IoT in healthcare. billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

260

260

BioPharma Dive

MAY 21, 2024

pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

119

119

STAT

OCTOBER 27, 2023

The American College of Emergency Physicians predicted in a 2021 study that there would be a surplus of nearly 8,000 emergency physicians by 2030. While much of the health care workforce is battling staff shortages, the emergency medicine field is trying to figure out how to manage a potential oversupply of physicians. Read the rest…

Hospitals 354

Hospitals 354

STAT

NOVEMBER 12, 2024

AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it achieve its goal of nearly doubling its revenue to $80 billion by 2030.

Chemotherapy 266

Chemotherapy 266

Pharma Times

NOVEMBER 30, 2021

Following its recent approval of an injectable HIV-1 treatment from the National institute for Health and Care Excellence (NICE), GlaxoSmithKline (GSK) has high hopes in developing a cure for the virus in the future.

151

151

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Compounding 59

Compounding Labelling 59

Express Pharma

JUNE 4, 2024

As the Indian pharmaceutical industry is projected to grow from USD 65 billion in 2024 to USD 130 billion by 2030, with a CAGR of over 10 per cent, the expo highlights its potential trajectory.

Packaging 105

Packaging Biosimilars Vaccines Labelling 105

STAT

APRIL 24, 2024

A rise in the number of younger Americans diagnosed with colorectal cancer worries me — early-age onset colorectal cancer is expected to surge by more than 140% by 2030. As a gastroenterologist and cancer researcher, my mission is to help my patients live longer, healthier, and cancer-free lives.

347

347

STAT

DECEMBER 5, 2023

Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Plenty of people in pharma and at the banks that invest in it seem to think so. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

Drug Pricing 312

Drug Pricing Drug Development 312

Express Pharma

AUGUST 21, 2024

As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion by 2030. billion in 2030, 15 times less than the combined valuation of the two leading companies.” billion and Zepbound forecast to generate $27.3

Diabetes 124

Diabetes 124

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

JUNE 14, 2023

The recommendations to combat AMR propose that there should be a 20% reduction in the total human consumption of antibiotics by 2030 alongside an even larger pushback against their use in animals, per the 13 June announcement.

Long-Term Care Facilities 52

Long-Term Care Facilities Documentation Hospitals 52

pharmaphorum

DECEMBER 7, 2023

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.

95

95

STAT

JUNE 7, 2024

They are driving a race among drugmakers for a slice of a market that could exceed $100 billion by 2030. Weight loss treatments have the potential to revolutionize health care in rich countries.

251

251

The Guardian - Pharmaceutical Industry

OCTOBER 16, 2022

ahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells Vaccines that target cancer could be available before the end of the decade, according to the husband and wife team behind one of the most successful Covid vaccines of the pandemic.

Vaccines 103

Vaccines 103

STAT

FEBRUARY 29, 2024

It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.)

Drug Development 360

Drug Development 360

STAT

MAY 21, 2024

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

330

330

Outsourcing Pharma

SEPTEMBER 12, 2023

The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.

87

87